Skip to main
OCS
OCS logo

OCS Stock Forecast & Price Target

OCS Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oculis Holding AG has demonstrated a positive trajectory in its clinical developments, particularly with the strong Phase 2 ACUITY results for OCS-05 in acute optic neuritis, which indicate significant improvements in low contrast visual acuity—an encouraging indicator for future trials. The initiation of the PIONEER trials, projected for late 2025 and into 2026, reflects the company's strategic commitment to expediting its pipeline, supported by favorable discussions with the FDA. Additionally, the promising responder rates for OCS-01 in its trials further enhance the company's growth potential and overall positive outlook in the biopharmaceutical sector.

Bears say

Oculis Holding faces significant challenges due to potential delays in clinical development, regulatory approvals, and commercialization timelines, which could lead to extended development periods and increased costs. The company reported a net loss of CHF 16.9 million in 3Q25 and is also contending with substantial market competition from existing or emerging therapies that may hinder market penetration and pricing power. Furthermore, there are inherent clinical risks associated with Oculis' development candidates OCS-01, OCS-02, and OCS-05, as failure to demonstrate adequate efficacy or safety in trials could adversely impact its business.

OCS has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Oculis Holding AG and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Oculis Holding AG (OCS) Forecast

Analysts have given OCS a Strong Buy based on their latest research and market trends.

According to 6 analysts, OCS has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $42.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $42.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Oculis Holding AG (OCS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.